GlassScriptPhysician profile
Kathryn K Arner
NPI 1720388655
$2,220.48
in general payments reported to CMS, 2019-2025
17 companies · $276 in 2025
The $276 reported for 2025 was more than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $44.63 · 2022: $296 · 2023: $659 · 2024: $945 · 2025: $276.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,880.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,879.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $957.39 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $415.51 | 2023-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $153.63 | 2023-2024 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $121.64 | 2021-2024 | Entyvio, Eohilia |
| Nestle Healthcare Nutrition INC. | $95.61 | 2023 | |
| Gilead Sciences, INC. | $88.95 | 2024 | |
| Janssen Biotech, INC. | $69.25 | 2023-2024 | Stelara |
| Lilly USA, LLC | $63.27 | 2024 | Omvoh |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.94 | 2023-2024 | Cyltezo |
| Ironwood Pharmaceuticals, INC | $32.83 | 2023 | Linzess |
| Fresenius Kabi USA, LLC | $32.19 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $31.28 | 2023 | Dupixent |
| Madrigal Pharmaceuticals | $24.94 | 2024 | Resmetirom |
| Intercept Pharmaceuticals, INC. | $23.93 | 2023 | Ocaliva |
| Ferring Pharmaceuticals INC. | $20.96 | 2023 | Rebyota |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $18.03 | 2023 | Dificid |
| Ardelyx, INC. | $17.13 | 2023 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Arner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.